This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The TSX Venture Exchange gained 6.02 points to 806.90 Friday, ending the week up 13.26 points. Two capital pool shells completed their qualifying transactions and began trading today as shell graduates. First, Benoit Chotard's Orletto Capital Inc. closed a pharmaceutical QT and now trades as Devonian Health Group Inc. (GSD). It reached an intraday high of 95 cents before closing at 80 cents on 45,988 shares. Second, Peter Hughes's Broome Capital Corp. (BCP) closed a Saskatchewan uranium QT. It traded an odd lot of two shares at five cents.

Mr. Chotard's Orletto Capital acquired a company that is conducting clinical trials for a plant-based drug called Thykamine. The drug is meant to treat atopic dermatitis, which is a type of skin inflammation, and ulcerative colitis, which is a type of bowel inflammation. The company's lab is in Montmagny, Que. Orletto rolled back 1 for 2.75, which left it with 1,997,454 postconsolidated shares issued, then it issued 31,230,531 postconsolidated shares to its target's shareholders. The shell also issued 19,966,523 multiple voting shares (not listed) to its target's president, Dr. Andre Boulet. Each multiple voting share carries six votes. Dr. Boulet, who holds a PhD in physiology-endocrinology, co-invented Devonian's plant processing technology.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS